Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World Cohort
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.08.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Rachel E Christensen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Sezary Syndrome, Mycosis Fungoides, Antibodies, Monoclonal, Humanized, Skin Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, NIH National Cancer Institute.
Abstract (Originalsprache)
BACKGROUND: Mogamulizumab is more effective in treating the blood component of mycosis fungoides (MF) and Sezary syndrome (SS), though some patients also experience significant skin improvement. The characteristics distinguishing those with a favorable skin response remain unclear. OBJECTIVES: This study aimed to characterize MF/SS patients achieving skin response on mogamulizumab. METHODS: A retrospective chart review at a single cancer center included adult MF/SS patients who received at least one mogamulizumab cycle with follow-up. Skin response (≥ 50% clearance) and blood response (≥ 50% decrease in neoplastic cells/µL) were assessed alongside demographics, disease staging, and prior therapies. RESULTS: Among 56 patients (MF = 35; SS = 21), 43% achieved skin response, with a median time of 2.3 months (range 0.5-6.4). Blood response occurred in 90%, with a median time of 1.8 months (range 0.2-23). Skin-response was highest in patients with blood response (64%), blood disease (B2, 61%), and SS (57%) and was significantly associated with decreasing circulating Sezary cells (P < .001). Among patients without blood involvement (B0), 24% achieved skin response, primarily in erythrodermic cases (71% versus 11%, P = .01). CONCLUSIONS: Mogamulizumab appears effective in inducing skin responses, particularly in advanced-stage and high blood-stage disease. Even in patients without blood compartment involvement, mogamulizumab therapy may still be beneficial, especially for patients with erythroderma. Skin responses are less common in early-stage MF. Patients with both advanced blood and skin disease may benefit from initiating mogamulizumab simultaneously with skin-directed therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center New York, NY.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: gellers@mskcc.org.
Förderung
- NCI NIH HHS
- National Institutes of Health
- NIH National Cancer Institute
Zitieren
APA
Christensen, R. E., Stuver, R., Dusza, S., Epstein-Peterson, Z. D., Ghione, P., Horwitz, S. M., Johnson, W., Moskowitz, A. J., Myskowski, P., Pulitzer, M., & Geller, S. (2025). Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World Cohort. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.08.008
Vancouver
Christensen RE, Stuver R, Dusza S, Epstein-Peterson ZD, Ghione P, Horwitz SM, et al. Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World Cohort. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.08.008
BibTeX
@article{Christensen2025,
author = {Christensen, Rachel E and Stuver, Robert and Dusza, Stephen and Epstein-Peterson, Zachary D and Ghione, Paola and Horwitz, Steven M and Johnson, William and Moskowitz, Alison J and Myskowski, Patricia and Pulitzer, Melissa and Geller, Shamir},
title = {Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World Cohort},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.08.008}
}
EUVIMED